Actinium Pharmaceuticals, Inc.

ATNM

US00507W2061

Biotechnology & Medical Research

Market Closed - Nyse Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
7.45 ^USD	+0.95%		+6.89%	+46.65%

Jul. 01	Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2000 Value Index	CI
Jul. 01	Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000 Value Index	CI

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Microcap Value Index

July 30, 2024

Latest news about Actinium Pharmaceuticals, Inc.

Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2000 Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000 Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 2500 Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Microcap Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell Small Cap Comp Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc.(NYSEAM:ATNM) dropped from Russell 3000E Value Index	Jun. 30	CI
Actinium Pharmaceuticals, Inc. Highlights Oral Presentation at EHA 2024 Annual Congress Featuring Improved Outcomes in TP53 Positive Patients Receiving Iomab-B in the Phase 3 SIERRA Trial	Jun. 14	CI
Actinium Announces Results of Actimab-A + CLAG-M Combination Trial Highlighted in Oral Presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	Jun. 11	CI
Actinium Highlights Mutation Data from the Phase 3 Sierra Trial of Iomab-B and Novel Linker Technology to Support Solid Tumor Antibody Radiation Conjugate Development At the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting	Jun. 10	CI
Transcript : Actinium Pharmaceuticals, Inc. - Special Call	May. 20
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in Tp53 Positive Patients At the Eha 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 Sierra Trial	May. 14	CI
Stephens Initiates Actinium Pharmaceuticals With Overweight Rating, $25 Price Target	May. 14	MT
Actinium Pharmaceuticals, Inc. Announces KOL Webinar to Highlight Recently Announced Iomab-ACT Trial with Leading FDA Approved Commercial CAR T-Cell Therapy Being Led by the University of Texas Southwestern	May. 07	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Actinium Pharmaceuticals, Inc. Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting	Apr. 18	CI
Actinium Pharmaceuticals, Inc. Announces Iomab-B Phase 3 Sierra Trial Results Demonstrating Survival Benefit in High-Risk Relapsed or Refractory Acute Myeloid Leukemia Patients with TP53 Mutations Accepted for Oral Presentation At the 50Th European Bone Marrow Transplant Annual Meeting	Apr. 01	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29	CI
Actinium Pharmaceuticals Announces Clinical Trial to Study Iomab-ACT Targeted Radiotherapy Conditioning with FDA Approved Commercial CAR T-Cell Therapy	Mar. 26	CI
Maxim Adjusts Actinium Pharmaceuticals' Price Target to $30 From $20, Maintains Buy Rating	Mar. 19	MT
B. Riley Adjusts Price Target on Actinium Pharmaceuticals to $16 From $20, Maintains Buy Rating	Dec. 11	MT
Actinium Pharmaceuticals, Inc. Announces Results from the Phase 3 SIERRA Trial of Iomab-B Were Presents in an Oral Presentation At the 65th Annual American Society of Hematology Meeting & Exposition	Dec. 11	CI
Actinium Pharmaceuticals, Inc. Appoints Lynn Bodarky as Chief Business Officer	Nov. 03	CI
Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Actinium Pharmaceuticals, Inc. Announces Oral Presentation at ASH Annual Meeting	Nov. 02	CI
National Institutes of Health Awards Actinium A Small Business Technology Transfer Grant Extension to Actinium Pharmaceuticals, Inc	23-10-04	CI

Chart Actinium Pharmaceuticals, Inc.

Duration

Period

More charts

Actinium Pharmaceuticals, Inc. is a late-stage biopharmaceutical company. The Company is engaged in developing targeted radiotherapies to improve survival for people who have failed existing oncology therapies. The Companyâs advanced pipeline candidates include Iomab-B (pre-BLA & MAA (EU)) and Actimab-A. Iomab-B is an induction and conditioning agent prior to bone marrow transplant. Actimab-A is a therapeutic agent, have demonstrated potential to extend survival outcomes for people with relapsed and refractory acute myeloid leukemia. The Company focuses on advance Iomab-B for other blood cancers and next generation conditioning candidate Iomab-ACT to improve cell and gene therapy outcomes. The Company holds patent applications including several patents related to the manufacture of the isotope Ac-225 in a cyclotron. Actinium-225 is a potent alpha-particle emitter that has high linear energy transfer capable of killing targeted cancer cells via double-strand breaks in DNA.

Sector

Biotechnology & Medical Research

Calendar

2025-03-13 - Q4 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.45 USD

Average target price

25.4 USD

Spread / Average Target

+240.94%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ACTINIUM PHARMACEUTICALS, INC.	+46.65%	220M
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	127B
REGENERON PHARMACEUTICALS, INC.	+25.25%	117B
ARGENX SE	+25.56%	27.77B
BIONTECH SE	-19.51%	20.44B
GENMAB A/S	-14.36%	16.62B
BEIGENE, LTD.	-15.63%	15.92B
WUXI APPTEC CO., LTD.	-46.67%	14.94B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.74B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs